NCT00051662已完成1 期
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Efficacy and Pharmacokinetics of Efalizumab in Subjects With Psoriatic Arthritis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)
详细描述
A phase II, randomized, double-blind, placebo-controlled study to:
- Demonstrate the clinical efficacy of efalizumab in the treatment of subjects with psoriatic arthritis (PsA).
- Evaluate the safety, tolerability and pharmacokinetics of efalizumab in the treatment of subjects with PsA
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
撤回
2 期
A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19COVID-19NCT04770467Brii Biosciences, Inc.
已完成
2 期
Safety and Efficacy Study of Omalizumab to Treat Allergic AsthmaAllergic AsthmaNCT01976208Shanghai Zhangjiang Biotechnology Limited Company630
已完成
2 期
A Trial of BTT1023 in Patients With Primary Sclerosing CholangitisPrimary Sclerosing CholangitisNCT02239211University of Birmingham23
已完成
1 期
A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's DiseaseCrohn DiseaseNCT03681067University of Birmingham5
已完成
2 期
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.Rheumatoid ArthritisNCT00034203XOMA (US) LLC